학술논문

Host sirtuin 2 as an immunotherapeutic target against tuberculosis
Document Type
Academic Journal
Source
eLife. July 22, 2020, Vol. 9
Subject
Epigenetic inheritance -- Health aspects
Macrophages -- Health aspects
Antitubercular agents -- Health aspects
Medical research -- Health aspects
Immunotherapy -- Health aspects
Tuberculosis -- Development and progression
T cells -- Health aspects
Biological sciences
Development and progression
Health aspects
Language
English
ISSN
2050-084X
Abstract
Mycobacterium tuberculosis (Mtb) employs plethora of mechanisms to hijack the host defence machinery for its successful survival, proliferation and persistence. Here, we show that Mtb upregulates one of the key epigenetic modulators, NAD+ dependent histone deacetylase Sirtuin 2 (SIRT2), which upon infection translocate to the nucleus and deacetylates histone H3K18, thus modulating the host transcriptome leading to enhanced macrophage activation. Furthermore, in Mtb specific T cells, SIRT2 deacetylates NF[kappa]B-p65 at K310 to modulate T helper cell differentiation. Pharmacological inhibition of SIRT2 restricts the intracellular growth of both drug-sensitive and resistant strains of Mtb and enhances the efficacy of front line anti-TB drug Isoniazid in the murine model of infection. SIRT2 inhibitor-treated mice display reduced bacillary load, decreased disease pathology and increased Mtb-specific protective immune responses. Overall, this study provides a link between Mtb infection, epigenetics and host immune response, which can be exploited to achieve therapeutic benefits.
Byline: Ashima Bhaskar, Santosh Kumar, Mehak Zahoor Khan, Amit Singh, Ved Prakash Dwivedi, Vinay Kumar Nandicoori Introduction Tuberculosis (TB), a deadly disease caused by the intracellular pathogen Mtb, has existed [...]